The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.
Medibank is seeking to shield from a shareholder class action an “irrelevant” post-incident report by Deloitte into its massive October 2022 data breach.
As Mineral Resources and WiseTech face shareholder glare over accusations levelled at their billionaire bosses, it is Herbert Smith Freehills that their embattled boards have turned to.
United Petroleum will not face cross-claims by franchisees, with a judge calling the bid “a very colourable application” to create overlap with a class action in the Supreme Court.
Investment manager Salter Brothers has sued XL Insurance, saying it has “unreasonably delayed” covering the costs of defending a former client’s lawsuit alleging misleading conduct.
ASIC has won its case against insurer HCF Life over a pre-existing condition term that was likely to mislead the public, but failed to convince the court that it was an unfair contract term.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
The corporate regulator has warned financial services and credit licensees to get ahead of the curve in regulating the use of AI, particularly in the face of novel risks that include algorithm bias.
Santos’ plan to reach net zero greenhouse gas emissions by 2040 was “little more than a series of speculations”, a shareholder group has said on the first day of trial in a landmark greenwashing case.
S&P is free to pay for a Rolls-Royce defence in “Rolls-Royce litigation” that alleges the agency engaged in fraud in assigning ratings to risky financial products, a judge has said.